The quarterly scientific journal

In the news

19/02/2024

Leveraging CHO cell potential in R&D and cGMP

  • Cell banking
  • Characterization
  • CHO cell
  • Clonal Selection
  • GMP
  • manufacturing
  • R&D
  • Single Cell Cloning
  • Storage

With 25 years of experience handling hundreds of cell lines, Clean Cells is your reliable partner on both adherent and suspension models with cloning and manufacturing technologies for CHO cell lines. Our extensive portfolio of QC assays also ensures the best level of characterization for the most potent and safe CHO cells, with complementary and novel methods for monoclonal antibody characterization (ADCC).

Read more
10/02/2024

Clean Cells, your partner for single cell cloning to cGMP cell banks

  • Capabilities
  • cell banks
  • Clonal Selection
  • end-to-end
  • manufacturing
  • Single Cell Cloning

As a contract organization specializing in cGMP cell & virus banking and QC testing, Clean Cells knows the importance of qualitative cell line development. We thus implemented Solentim’s VIPS® PRO, a state-of-the-art single cell cloning platform to isolate potent clones and characterize the monoclonality of biotherapeutics producing cell lines, with an increased traceability as part of a regulatory compliant approach.

Read more
24/10/2023

Increasing biologics manufacturing capacities

  • banques virales
  • BPF
  • Capabilities
  • Cell banking
  • cell banks
  • end-to-end
  • Facilities
  • GMP
  • manufacturing
  • Starting material

With 23+ years of experience handling hundreds of cell and virus models, Clean Cells has positioned itself as a leader in cell and virus banking, providing complementary characterization and storage services. Our state-of-the-art cGMP facility launched earlier this year now welcomes our biologics manufacturing capacities, providing 8 new clean rooms designed for all types of biopharma projects and equiped to meet production specifications for both adherent and suspension cells.

Read more
Scale-XTM bioreactor
22/06/2023

Assessing the scale-X(TM) bioreactor’s biomanufacturing capacities on Vero cells

  • Capabilities
  • Cell banking
  • cells bank
  • Facilities
  • Naobios

To further extend their biomanufacturing capabilities and cater to Univercells clients' growing needs, Naobios has recently conducted a comprehensive assessment of the performance of Vero cells cultured within the scale-X(TM) bioreactor provided by Univercells Technologies. This assessment aimed to evaluate the compatibility and efficiency of the Vero cell line in this novel bioreactor system for viral-based bioproduction.

Read more
03/05/2023

A new facility to extend biopharma services

  • Biosafety testing
  • cell banks
  • end-to-end
  • Facilities
  • Testing
  • virus banks

Last January, Clean Cells opened its new cGMP-compliant facility, a cutting-edge 5 300 m2 platform which considerably extends biopharma capacities. Additional biologics testing capacity, extended cell and gene therapy services, end-to-end biomanufacturing and storage: Clean Cells’ new site opens a new chapter in the company’s rich history.

Read more
06/12/2022

Characterization and control testing of lentiviral vectors and derived products

  • Gene Therapy
  • lentiviral vectors
  • RCL Pool assay

Clean Cells has partnered with customers on dozens of gene therapy projectsinvolving testing of lentiviral vectors and CAR-T cell therapies.

Read more
14/09/2022

Integrated solution for cell banking and characterization

  • Biological starting matérial
  • Cell banking
  • cells bank
  • Characterization
  • Facilities
  • manufacturing
  • Master Cell Banks
  • MCB
  • Storage
  • virus bank

Clean Cells offers an integrated solution for cell bank generation in GMP and non-GMP-settings together with full characterization services and additional long-term storage options to secure valuable material.

Read more
17/05/2022

GMP biomanufacturing in a BSL-3 suite

  • BSL3
  • Capabilities
  • Facilities
  • manufacturing

A GMP biomanufacturing expert, Naobios has worked with numerous viruses requiring specific biocontainment procedures. Our state-of-the-art BSL-3 suite welcomes hazardous microbes used for the generation of virus-based therapeutic products.

Read more